Allicin-loaded soluplus polymeric micelles differentially modulate doxorubicin response in adenocarcinoma and myocardial cell models Authors: Khaldoun J Al-Hadid, Walhan Alshaer, Baidaa AlQuaissi, Bayan Ziad Al-Momany, Nowar Alsarayreh, Dana A Alqudah, Tasneem Alsheleh Published: 2026 ABSTRACT AbstractAllicin, an organosulfur compound derived from garlic, exhibits effective cellular activities, but its administration is often hindered by poor bioavailability and relative instability. To address these limitations, Soluplus-based polymeric micelles were engineered to encapsulate allicin and evaluated for their chemosensitizing or chemoprotective capacity with doxorubicin. The micelles displayed uniform spherical nanoparticles (~ 74 nm, PDI ~ 0.21) with nearly complete encapsulation efficiency. Compared with free allicin, micellar formulations showed markedly reduced release (~ 16% vs. ~50%) at physiological temperature, indicating improved drug retention. Stability assessments revealed particle size and zeta potential were time-dependent but unaffected by temperature. FTIR confirmed successful encapsulation, while thermogravimetric analysis demonstrated thermal stability up to 250–300 °C. In vitro, treatment with the allicin-Soluplus micelles prior to doxorubicin treatment exhibited a cell-model-dependent modulation of doxorubicin response. A partial protective metabolic response was observed in myocardial cells H9C2 and colorectal adenocarcinoma CACO2 cells. An opposite effect was observed on prostate adenocarcinoma DU145 cells, in which allicin exhibited a chemosensitizing effect with doxorubicin. These preliminary in vitro findings highlight Soluplus micelles as a promising delivery platform to stabilize allicin and potentiate its therapeutic effect in oncotherapy.Keywords: Allicin, Soluplus, nanocarriers, doxorubicin, cancer therapy, polymeric micellesSubject terms: Biotechnology, Cancer, Drug discovery, Nanoscience and technology Introduction The global burden of cancer remains a clinical challenge to public health despite the significant advancements in oncotherapy. Rising incidence states, multidrug resistance, tumor heterogeneity, and systemic drug toxicities are factors accounting for poor treatment responses and high cancer-associated mortality rates1–3. While conventional therapeutic methods, such as chemotherapy, wield considerable efficacy, several factors hinder the procurement of satisfactory therapeutic outcomes. Such factors include off-target toxicities that cause significant patient discomfort due to the systemic exposure to chemotherapy4–6. In addition, treatment resistance is a reciprocal escalation, wherein alternative bypass mechanisms are often triggered in response to diverse treatment options7,8. Moreover, the lack of treatment selectivity is evidenced by drug accumulation at off-target sites, which presents one of the driving causes of adverse treatment effects9,10. Researchers are studying the application of natural compounds in treating cancer and combining them with chemotherapy drugs to enhance their chemosensitizing or chemoprotective properties. Many different natural compounds have been tested for their specific pharmacological properties as adjunct therapies that increase the efficacy of cancer treatment, and other natural compounds have been identified as potential agents to overcome drug resistance to chemotherapeutic agents11,12. One example of a natural compound that has been evaluated as a potential chemotherapeutic agent is allicin, which is an organosulfur compound that results from the enzymatic transformation of alliin in garlic (Allium sativum). Numerous studies have indicated that allicin has antitumor activity by inducing apoptosis, modulating oxidative stress, and regulating anti-inflammatory signal transduction pathways13–15. Although allicin displays such positive results in an in vitro setting, its clinically translated benefits may be lessened due to factors including chemical instability and rapid degradation before testing. This has a proportionate effect on allicin’s bioavailability. The potential for allicin to be effective as a therapeutic agent diminishes primarily because multiple studies show that allicin synthetic degradation occurs soon after it is formed and is subject to variable levels of instability as influenced by physicochemical properties such as temperature and pH. The structure of allicin places it among highly reactive sulfur compounds, but because it frequently does not remain intact when it reaches a target tissue, the overall bioavailability of allicin will often be relatively low16–19. Many biological factors affect allicin’s overall bioavailability, creating barriers to using the complete range of allicin’s therapeutic potential20. Current scientific progress gives an indication for creating new formulation strategies via nanotechnology-based delivery systems to resolve these fundamental physicochemical limitations. Drug delivery systems emerged to offer myriad advances in cancer drug delivery. The design of nanocarriers to encapsulate the compound of interest and release it at the targeted site not only enhances the bioavailability of the compound but also reduces its release at off-target sites, reducing its adverse effects21. Nanocarriers such as polymeric micelles provide a multifunctional platform for the delivery of a diverse set of bioactive compounds. The self-assembled nanostructures of these nanocarriers consist of amphiphilic block copolymers that create a hydrophobic core for encapsulating poorly soluble molecules and a hydrophilic shell for providing stability and improving the circulation time of the nanocarrier in an aqueous environment. The architecture of nanocarriers enhances solubility, stability, and controlled release while supporting nanocarrier-mediated delivery and cellular uptake of the bioactive compound22–24. There is evidence for the successful encapsulation of allicin in micelle-based systems. For example, nonionic micelles made from Polysorbate 80 demonstrated successful encapsulation of allicin as well as a significant reduction in the rate of degradation of allicin during 25 °C storage while maintaining allicin’s bioactivity and physiochemical characteristics25. In cancer nanomedicine, the compatibility between the nanocarrier and the loaded compound is a profound milestone for the successful delivery of the active component, in which the release kinetics, stability, and bioavailability are all dependent on this landmark26. As such, the design of a nanocarrier for allicin that maintains its properties while ensuring good encapsulation and releasing profile remains an important niche to investigate. Soluplus (a polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol-graft copolymer) is a novel micellar vehicle with a unique solubilizing ability, biocompatibility, and drug-enhancing permeability. Soluplus-based formulations continue to show promise for improving the solubility and stability of poorly water-soluble drugs, making them attractive as vehicles for natural products such as allicin27,28. Previous works have demonstrated that Soluplus-micelles can increase the solubility of an encapsulated compound and, at the same time, provide stability against decomposition25,29. As such, the first objective of this study is to determine the feasibility of preparing and characterizing Soluplus-loaded micelles with allicin, and to test its effects in combination with doxorubicin. The combination of natural compounds with traditional chemotherapeutics can potentially create a promising outcome when treated simultaneously. Therefore, natural compounds have a lot of potential to be used in combination with established chemotherapeutics, including anthracyclines, such as doxorubicin. Although doxorubicin is one of the most effective chemotherapeutic agents used to treat various types of cancers, it is often limited by several adverse effects, including dose-dependent cardiotoxicity30–32. Thus, allicin treatment in combination with doxorubicin may modulate doxorubicin response in myocardial and cancer cell models, presenting the second aim of this work, which is to evaluate whether allicin-loaded Soluplus micelles could modulate doxorubicin response in a myocardial model and two adenocarcinoma cell models, CACO2 and DU145. This work presents the design and characterization of an allicin-loaded Soluplus nanocarrier and evaluates its in vitro effects in combination with doxorubicin. The study focused on cytotoxicity, cellular uptake, and apoptosis induction to explore whether allicin encapsulation could improve its delivery and modulate doxorubicin response in cancer-related cellular models. By addressing the instability and delivery limitations of allicin, these findings support the potential of Soluplus micelles as a nanocarrier platform for improving the delivery of natural compounds in preliminary in vitro models. Micelle-based systems have also been investigated for combination cancer therapy, including ROS-responsive co-delivery platforms designed to deliver complementary therapeutic agents33. However, the present study used a sequential treatment approach, in which allicin was loaded into Soluplus micelles before doxorubicin exposure, rather than co-encapsulating both agents within the same micelle. Materials and methods Formation of allicin-loaded soluplus micelles by ethanol injection The preparation of allicin-loaded Soluplus micelles was performed following a previously published protocol34. Briefly, 1.0 mg of allicin (Genochem World SL., Spain) was mixed with 10 mg Soluplus® (BASF, Germany) and dissolved in 20% ethanol (v/v) in a total volume of 1 ml. The mixture was then slowly injected into phosphate-buffered saline (PBS) under continuous stirring to promote self-assembly of micelles. Residual ethanol was removed by heating and stirring at 65 °C, 600 rpm for 2 h. The formulation was subsequently purified using dialysis tubing (12.5 Kda), incubated overnight with buffer (PBS), and then stored at 4 °C. Freshly prepared and purified micelles were frozen at -70 °C for 24 h, followed by freeze-drying for 24 h at -55 °C. Quantification of allicin loaded soluplus micelles content using ellman assay Quantification of allicin loaded Soluplus Micelles content was conducted using the Ellman assay according to the manufacturer’s instructions (Thermofisher, USA). L-cystine present in the Ellman reagent reacts with allicin to form the yellow-colored 2-nitro-5-thiobenzoate anion (TNB), which can be measured spectrophotometrically at 412 nm using a Nanodrop spectrophotometer (Thermo Fisher Scientific, USA). Additional details on the calibration curve and encapsulation-efficiency calculation are provided in the Supplementary. Physical characterization of the allicin-loaded micelles Dynamic Light Scattering (DLS) was used to measure the mean diameter of the Allicin-loaded Soluplus Micelles using a Zetasizer Nano ZS instrument (Malvern Instruments, UK). The polydispersity index (PDI) was recorded to evaluate the uniformity of the size distribution. The zeta potential, indicating the surface charge of the micelles, was determined using the same instrument. Before measurement, all formulations were diluted 1:20 with deionized water. Morphological features and particle size distribution were examined by scanning electron microscopy (SEM) (Versa 3D, FEI) and transmission electron microscopy (TEM) (FEI, Eindhoven, Netherlands). In vitro release Freshly prepared allicin-Soluplus micelles release profile was evaluated over time. 1 mL of the allicin-Soluplus micelles and 1 mg of free allicin dissolved separately in 1 mL of PBS were prepared, transferred into a dialysis membrane (12.5 kDa), and immersed in 10 mL of PBS at two temperature points (4 °C and 37 °C). Samples were collected from the external buffer that immersed the dialysis membrane at the following time intervals (1 h, 4 h, 6 h, 24 h, 48 h, and 72 h). Fresh PBS was added to the external buffer that immersed the dialysis membrane with an equal volume as the sample volume. Physical stability To evaluate the stability of the micelles, 1.0 mL of the allicin loaded Soluplus micelles and 1 mg of free allicin were dissolved separately in 1 mL of PBS and stored at two temperature points (4 °C and 37 °C). Samples were collected at predetermined time points: 1 h, 4 h, 6 h, 24 h, 48 h, 72 h, 1 week, 2 weeks, and 1 month. For each sample collected, size and charge were measured. Fourier transform infrared (FTIR) spectroscopy For rupturing the allicin-Soluplus micelles, 1.0 mg of lyophilized allicin-Soluplus micelles was submerged in 50 µL of absolute ethanol. Fourier Transform Infrared (FTIR) Spectroscopy was conducted under identical acquisition parameters for both intact and ruptured samples using Perkin-Elmer Spectrum Two with a universal ATR FTIR Spectrometer (LiTaO3 detector) over a spectral range of 4000 to 400 cm− 1. Thermogravimetric analysis (TGA) The thermal stability and decomposition profile of the allicin-Soluplus micelles were measured by thermogravimetric analysis (TGA). To perform this test, 2.0890 mg of the lyophilized sample was accurately weighed and subjected to controlled heating conditions. This analysis was conducted using a Mettler Toledo instrument (TGA/DSC 2, Greifensee, Switzerland) from 25 °C to 600 °C at a heating rate of 10 °C/min. Cell culture The allicin-Soluplus micelles were evaluated in a panel of cell lines, including DU145 (human prostate carcinoma cells), CACO-2 (human colorectal adenocarcinoma cells), and H9C2 (embryonic BD1X rat cardiomyoblasts). All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained as adherent monolayers in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco™). Media were supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; EuroClone, Italy), 1% penicillin–streptomycin solution (EuroClone, Italy), and 2 mM L-glutamine. Cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO₂ using a tissue culture incubator (Memmert, Schwabach, Germany). These models were selected to provide a preliminary comparison across myocardial, colorectal epithelial, and prostate adenocarcinoma contexts. Cell viability assay (MTT) Cells per well were seeded into 96-well plates (Corning, USA) at a seeding density of 9000 cells/well and allowed to adhere overnight. Allicin (Mw: 162.26 g.mol− 1) stock was prepared at a concentration of 1 mg/ml (6.2 mM), and cells were treated with a serially diluted allicin treatment ranging from 6.2 to 0.006 mM to determine its IC50 values in its free form. To study the effects of allicin on doxorubicin, cells were treated with 10 µM allicin; selected as a fixed low/sub-cytotoxic concentration below the determined IC50 values, allicin-Soluplus micelles, or 10 mg Soluplus for 24 h. After that, cells were treated with doxorubicin at concentrations ranging from 10 − 0 µM for 48 h. The control group was treated with doxorubicin without allicin prior to treatment. Cells were maintained in a humidified atmosphere at 37 °C with 5% CO₂. After incubation, the culture medium was aspirated, and 100 µL of fresh medium containing MTT reagent (Bioworld, USA) was added to each well. Plates were incubated for an additional 3 h at 37 °C to allow formazan crystal formation. Subsequently, 50 µL of DMSO was added to each well to dissolve the formazan crystals. Absorbance was measured at 560 nm using a Glomax plate reader (Promega, USA). Cell viability was calculated relative to untreated control wells, and the half-maximal inhibitory concentration (IC₅₀) was calculated using GraphPad Prism 8.0. Cellular uptake by flow cytometry and confocal, SEM All cell lines were treated with fluorescently labeled (Coumarin 6) allicin-Soluplus micelles, Soluplus-only micelles, free allicin, and Doxorubicin as a control. A total of 6 × 10⁵ cells per well were seeded into 12-well plates and incubated overnight to allow adherence. Cells were then exposed to 10 µM of allicin-Soluplus micelles, free allicin, or Soluplus-only micelles for 4 h, followed by the addition of 0.5 µM Doxorubicin for an additional 1 h, resulting in a total incubation time of 5 h. After treatment, cells were washed twice with PBS and detached using StemPro™ Accutase™ Cell Dissociation Reagent (Gibco™, UK). For quantitative analysis, cells were resuspended in PBS, and 10,000 events per sample were acquired using a BD FACS Canto II flow cytometer (BD Biosciences, USA). Data were analyzed with BD FACSDiva™ Software version 8.0. Fluorescence was detected using the FITC channel for Coumarin 6 and 568 nm emission channel for PE-Coumarin. For qualitative assessment, cells were seeded on coverslips and treated under the same conditions. Cells were visualized using confocal laser scanning microscopy. Apoptosis analysis by flow cytometry Apoptosis was evaluated using Annexin V/Propidium Iodide (PI) staining followed by flow cytometry. Briefly, 1 × 10⁵ cells per well were seeded into 12-well plates and allowed to adhere overnight. Cells were treated with 10 µM allicin-Soluplus micelles, free allicin, Soluplus, or 0.5 µM Doxorubicin as a control and incubated for 4 h. Doxorubicin was added to all treatments except the doxorubicin control group. All treated cells were incubated for 48 h. Cells were washed twice with PBS and detached using StemPro™ Accutase™ Cell Dissociation Reagent (Gibco™, UK). Cell pellets were resuspended and stained with Annexin V and Propidium Iodide using the Annexin V/PI Apoptosis Detection Kit (R&D Systems, USA) according to the manufacturer’s instructions. For each sample, 10,000 events were acquired using a BD FACS Canto II flow cytometer (BD Biosciences, USA) and analyzed with BD FACSDiva™ Software. The proportions of viable, early apoptotic, late apoptotic, and necrotic cells were determined based on fluorescence intensity in the FITC and PE channels. Statistical analysis Data was recorded in replicates and reported as mean ± SD. IC50 values were calculated by nonlinear regression using GraphPad Prism 8.0. Comparisons among multiple groups were performed using one-way ANOVA followed by appropriate post-hoc testing. Stability data involving time and temperature were analysed using two-way ANOVA. Statistical significance was defined as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Results and discussion Physical characterization The size, polydispersity index (PDI), and zeta potential of the allicin-Soluplus micelles and blank Soluplus micelles are shown in Fig. 1-A and B. Both the allicin-Soluplus micelles and blank Soluplus micelles exhibited an average size of 74.4 ± 3.12 nm and 79.95 ± 0.07 nm, respectively. Both formulations also showed particle mono-dispersity with an average PDI of 0.21 ± 0.06 and 0.22 ± 0.01, respectively. Both formulations showed slightly negatively charged particles with an average zeta potential of -3.0 ± 0.5 mV and − 5.0 ± 0.05 mV, respectively. Transmission electron micrographs showed spherical particle morphology as indicated in Fig. 1-C. Size distribution by intensity of (A) Allicin-loaded micelles, and (B) Unloaded Soluplus shows an average size of 74.4 ± 3.12 nm and 79.95 ± 0.07 nm, respectively. (C) Morphological TEM micrograph of the Allicin-loaded micelles shows a spherical morphology with an average size of 70 nm in diameter. The physical properties of nanocarriers are one of the main deterministic characteristics of their efficacy, as their size, dispersity, and zeta potential are important properties for their stability, drug loading capacity, and cellular uptake. The allicin-Soluplus micelles yielded to a size ≤ 100 nm with a PDI of 0.21 ± 0.06, reflecting an acceptable size for administration with sample monodispersity and homogeneity. The micelles showed a slightly negative surface charge indicated by the zeta potential, which is an advantageous property as nearly neutral nanocarriers were reported to be less susceptible to forming colloids with biological components due to surface charge, and also to reduce adsorption to immunogenic proteins as well, all of which enhance the availability of the loaded drug17,35–37. However, these near-neutral zeta potential values do not indicate strong electrostatic stabilization. Instead, the observed short-term physical stability of the Soluplus micelles is more likely supported by steric stabilization provided by the hydrated polymeric corona rather than by electrostatic repulsion38. Allicin encapsulation within a nanocarrier remains a challenging aspect due to its high instability and sensitivity to several factors. The design of a compatible delivery system for such a challenging compound provides insights into the advantages obtained from a nanocarrier in cancer therapy. Soluplus, as a copolymer that consists of polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol, provides a polymeric matrix effective for the stabilization and encapsulation of allicin. The amphiphilic nature of Soluplus facilitates the formation of the allicin-encapsulated micelles, where the hydrophobic domains of the polymer interact with the sulfur-containing groups in allicin to mitigate its rapid degradation and reactive volatility17,20,39–41. Driven by hydrogen bonding and hydrophobic interactions, this encapsulation mechanism successfully entrapped allicin at an apparent encapsulation efficiency of 99.99%, confirmed by calibrating allicin using UV-vis. The unique chemical architecture of Soluplus has enabled the formation of micellar structures in aqueous environments, aiming at improving the bioavailability of allicin by overcoming the challenges posed by its low aqueous solubility and instability. This is particularly important as the allicin-Soluplus micelles preserved the encapsulated allicin at both temperatures, maintaining the drug load in storage conditions to prevent drug loss during storage, and maintaining the drug load at physiological conditions to prevent leakage at off-target sites. This release behavior suggests improved retention of allicin within the micellar system and reduced premature leakage; however, intracellular release after cellular uptake was not directly assessed and requires further validation. The dialysis assay reflects detectable allicin/Ellman-reactive species in the external medium and may be influenced by diffusion, membrane transport, and degradation; therefore, biorelevant release media and kinetic modelling are needed in future work42,43. In vitro release Allicin release profiles were studied in its free form and in its encapsulated form within the allicin-Soluplus micelles at storage temperature (4 °C) and physiological temperature (37 °C) at a pH of 7.4 for 72 h, as indicated by Fig. 2. At 4 °C, an insignificant release amounting to 0.6% of allicin in its free form was observed. Whereas at 37 °C, a maximum release of allicin was observed with a cumulative amount of 50.6%, presenting contrary release behavior at the two studied temperatures. The allicin-Soluplus micelles, on the other hand, showed similar release profiles with a total cumulative allicin release of 15.8% and 17.5% at 4 °C and 37 °C, respectively, for the studied duration. This is particularly important as the allicin-Soluplus micelles preserved the encapsulated allicin at both temperatures, maintaining the drug load in storage conditions to prevent drug loss during storage, and maintaining the drug load at physiological conditions to prevent leakage at off-target sites. Thereby ensuring intracellular drug release after uptake within the target cells. This release behavior suggests improved retention of allicin within the micellar system and reduced premature leakage; however, intracellular release after cellular uptake was not directly assessed and requires further validation. The dialysis assay reflects detectable allicin/Ellman-reactive species in the external medium and may be influenced by diffusion, membrane transport, and degradation; therefore, biorelevant release media and kinetic modelling are needed in future work44,45. In vitro release profiles of Allicin in its free form and the Allicin-loaded micelles at storage temperature (4 °C) and physiological temperature (37 °C). Physical stability The physical stability of the allicin-Soluplus micelles was monitored in terms of size, PDI, and zeta potential for 1 month at storage temperature (4 °C) and physiological temperature (37 °C), as shown in Fig. 3. At both temperatures, the micelles had a good relative size, dispersity, and surface charge stability for 1 week; size fluctuations were observed from week 1 to 4. Two-way ANOVA of the stability study of the allicin-Soluplus micelles is shown in Table 1. Two factors account for the sources of variation: the time factor (from zero hours to 4 weeks) and the temperature factor (between 4 °C and 37 °C). The table indicates the contribution of each factor to the total variation and the combined effect of both factors on statistical significance. Particle size, sample dispersity, and zeta potential are shown to be mainly affected timewise, with no significant difference between the two temperatures studied. Physical stability of the Allicin-loaded micelles over a time period of 1 month at storage temperature (4 °C) and physiological temperature (37 °C). Table 1Two-way ANOVA of the stability study of the Allicin-loaded micelles.Source of Variation% of total variationP valueP value summarySignificant?Parameter: SizeInteraction41.44< 0.0001****YesTime33.89< 0.0001****YesTemperature1.1860.2128nsNoParameter: PDIInteraction18.490.0629nsNoTime38.260.0014**YesTemperature4.4740.0636nsNoParameter: Zeta potentialInteraction9.6880.0015**YesTime80.02< 0.0001****YesTemperature0.38450.2734nsNo Two-way ANOVA of the stability study of the Allicin-loaded micelles. In terms of size, PDI, and zeta potential, the particles showed a maintained stability for about a week at both storage temperatures (4 °C) and physiological temperature (37 °C). As indicated by Table 1, the major source of variation responsible for fluctuations of the studied physical properties is the time factor rather than the temperature factor, reflecting short-term particle physical stability in in vitro systems and storage conditions. while fluctuations after one week indicate that longer-term colloidal stability requires further optimization. This is particularly important for ensuring successful biodistribution if the nanocarrier and successful cellular uptake. Fluctuations in particle size not only affect its cellular interactions but also affect its release kinetics and maintenance of the encapsulated drug, all of which highlight the importance of structural stability on particle behavior in biological systems7,46,47. FTIR spectroscopy As shown in Fig. 4, infrared spectroscopic analysis of Allicin in its free form shows distinctive absorption bands at 3083 cm− 1 and 2980 cm− 1 for asymmetric and symmetric stretching of =CH2, respectively. Stretching of S = O is observed at 1075 cm− 1, and C = C stretching at 1634 cm− 1,985 cm− 1, and 917 cm− 1 bands show a strong intensity γ C-H deformation of =CH2, and 1423 cm− 1 shows δ C–H deformation of =CH2 48. Lyophilized Soluplus shows asymmetric -CH stretching at 2932 cm− 1, tertiary amid C = O stretching at 1628 cm− 1, and 1441 cm− 1 CH3 bending49. Upon Allicin encapsulation within the Soluplus, combination bands from both Allicin and the carrier polymer show slight band shifting towards 2922 cm− 1 and 2859 cm− 1 of =CH2 stretching, as well as a slight shifting of C = O at 1630 cm− 1. Rupturing of the Allicin-loaded Soluplus micelles with ethanol was conducted to validate Allicin encapsulation. Asymmetric -CH stretching within the Soluplus at 2932 cm− 1 is observed, with a slight band shifting of Allicin =CH2 at 2972 cm− 1. FTIR analysis of the Allicin-loaded micelles, allicin, and Soluplus in their free form, and the ruptured micelles. Thermogravimetric analysis (TGA) Thermogravimetric analysis of the allicin-Soluplus micelles was conducted to provide insights into the relative thermal stability in terms of mass retention over time with increasing temperatures. As shown in Fig. 5, mass retention of the formulation was maintained at temperatures up to 160 °C, in which a reduction in mass% was observed at higher following temperatures. Thermogravimetric analysis of the Allicin-loaded micelles. Uptake of the allicin-Soluplus micelles and doxorubicin The uptake of the coumarin-labelled allicin-Soluplus micelles, doxorubicin, and their combination was quantified by flow cytometry and qualitatively studied by confocal microscopy for their cellular localization, as described next. Quantitative uptake by flow cytometry Figure 6 shows the mean fluorescent intensity (MFI) of untreated cells, cells treated with allicin, allicin-Soluplus micelles, doxorubicin, doxorubicin combination with the allicin-Soluplus micelles, and doxorubicin combination with allicin. The fluorescence of the coumarin-labelled Allicin-Soluplus micelles was measured at the FITC filter, and the fluorescence of doxorubicin was measured at the PE filter. First, the uptake of the allicin-Soluplus micelles was drastically superior to the uptake of allicin in its free form in all studied cell lines, indicated by the FITC filter, including normal myocardium H9C2 cells, colorectal adenocarcinoma CACO2 cells, and the prostate adenocarcinoma DU145 cells, with P values ≤ 0.0001 for all cell lines. However, the greatest uptake of the allicin-Soluplus micelles was observed in DU15 cells, exceeding that of H9C2 and CACO2 by 3-fold, approximately. Mean fluorescent intensity (MFI) of the uptake of the coumarin-labelled allicin-Soluplus micelles and their combination with doxorubicin on H9C2, CACO2, and DU145 cell models. In H9C2 cells, the uptake of doxorubicin was the least upon its combination with allicin in its free form (P ≤ 0.0001), suggesting a potential protective effect of allicin on myocardial cells by reducing the uptake of doxorubicin, which has been extensively reported for its cardiotoxicity50,51. Meanwhile, no statistical difference was obtained between the uptake of doxorubicin or its combination with allicin-Soluplus micelles (P: 0.9544). This is mainly attributed to the fact that the delivery system in this work is designed for passive targeting, in which functionalization with a specific targeting moiety could further enhance the receptor-specific uptake and reduce non-specific uptake. In both CACO2 and DU145 cell lines, the highest uptake of doxorubicin was observed upon its combination with the allicin-Soluplus micelles, with P values of 0.0251 and 0.0002, respectively. Whereas no significant difference was shown between the uptake of doxorubicin and its combination with the micelles, with P values of 0.0509 and 0.2149 for CACO2 and DU145, respectively. In CACO2 cells, minimal uptake of the allicin-Soluplus micelles was observed compared to DU145, with an MFI of ≈ 2400 in CACO2 and an MFI of ≈ 9800 in DU145, as shown in Fig. 6. These differences are mainly attributed to the heterogeneity of cancer characteristics, including membrane topology, internalization pathways, and many other factors. The minimal uptake in CACO2 can be explained by its intrinsic barrier properties as well as the physicochemical characteristics of both the drug and carrier. First, CACO2 cells exhibit a high transepithelial electrical resistance as they differentiate into a tight epithelial monolayer, restricting passive entry and limiting intracellular accumulation52,53. Furthermore, cellular uptake is highly dependent on the nature of the drug, its molecular structure, and stability. Compounds with high instability in biological systems can exhibit negligible or variable uptake due to rapid degradation or interaction with the surrounding physicochemical factors. In fact, allicin is highly reactive and is prone to rapid chemical degradation and interaction with biological nucleophiles, which may further reduce its availability for cellular internalization39,54. In addition, Soluplus, as a solubilizing polymer41, has no direct evidence currently demonstrating enhanced uptake of Soluplus-based systems in CACO2 cells. Together, these factors may contribute to the observed minimal nanoparticle uptake in CACO2 cells. The relatively high uptake of the allicin-Soluplus micelles observed in DU145 may be associated with the altered membrane properties and enhanced endocytic activity in prostate cancer models55. Furthermore, the reshaped membrane lipid composition in a number of cancer models, including prostate cancer, is often reported to increase membrane fluidity and permeability, which explains the increased passive uptake of the studied nanocarrier. In addition, allicin is a small, lipophilic, and highly reactive, capable of interacting with membrane thiols, all of which may enhance its cellular internalization. Finally, the amphiphilic nature of Soluplus has enabled the formation of the nanoscale micelles, which may support passive cellular uptake. Collectively, these factors are likely to contribute to the high uptake of the allicin-Soluplus micelles in the DU145 model41,55,56. Qualitative uptake by confocal microscopy In H9C2 cells, confocal micrographs in Fig. 7 show the uptake of the coumarin-labeled allicin-Soluplus micelles with a general cytoplasmic localization. In normal cells, passive uptake of nanoparticles primarily occurs through non-specific endocytic pathways. In the absence of active targeting ligands, the internalization of nanocarriers is often governed by physicochemical properties such as size, surface charge, and hydrophilicity rather than receptor-specific interactions. Nanocarriers are typically trafficked through endosomal compartments following internalization. Cytoplasmic distribution is often observed in normal cell lines rather than organelle-specific localization, where uptake mechanisms are less upregulated compared to cancer cells, which lowers the internalization efficiency.57–59. Confocal images of the uptake of the coumarin-labelled allicin-Soluplus micelles and their cellular localization on H9C2, CACO2, and DU145 cell models. In CACO2 cells, minimal uptake of the allicin-Soluplus micelles was observed compared to DU145, which is compatible with the results in Sect. 3.6.1, indicating that the passive uptake of nanocarriers is often regulated by the membrane topology, nature of the cancer niche, and its interaction properties with the carrier60. Interestingly, a perinuclear localization of the allicin-Soluplus micelles is shown in the DU145 model, as indicated by Fig. 6. This phenomenon may be consistent with endocytic trafficking along the endo-lysosomal pathway. Following internalization, nanocarriers may be transported along microtubules towards the perinuclear region, where late endosomes and lysosomes accumulate near the microtubule-organizing center (MTOC). This results in the clustering of the particles around the nuclear membrane region37,61. Thus, the imaging data demonstrates localization of fluorescently labelled micelles but does not confirm cytosolic allicin release. Dedicated intracellular release or lysosomal escape studies would be needed to confirm the exact trafficking route and cytosolic release. Cell viability assay (MTT) To investigate the biocompatibility of the Soluplus micelles, cells were treated with 10–100 μm of the micelles without allicin loading. Similarly, cells were also treated with the same concentrations of the allicin-Soluplus micelles, as indicated by Fig. 8. Upon treatment with the unloaded Soluplus micelles, no reduction in viability; indicated by the optical density (OD) and compared to untreated cells, was observed at both concentrations in the three studied cell lines (H9C2, CACO2, and DU145), supporting the short-term biocompatibility of the Soluplus-based nanocarrier under these conditions. However, because Soluplus altered doxorubicin IC50 in some models, a possible carrier-associated contribution to drug response was also considered, as shown by the reduction in OD upon treatment with the allicin-Soluplus micelles. This is consistent with the broader understanding that polymeric micelles may influence drug solubilization, biological availability, and carrier-drug behaviour in biorelevant systems. This is consistent with the broader understanding that polymeric micelles may influence drug solubilization, biological availability, and carrier-drug behaviour in biorelevant systems62. Viability reflected by the OD of the three studied cell lines upon treatment with Soluplus unloaded micelles or the allicin-Soluplus micelles. After that, cells were treated with the allicin-Soluplus micelles, allicin, or Soluplus for 24 h, then treated with two-fold serial concentrations of doxorubicin ranging from 10 to 0 µM for 48 h, as shown in the dose-response curve in Fig. 9. This strategy aimed to test the modulation of doxorubicin response of allicin on doxorubicin, whether administered in its free form or encapsulated within the Soluplus micelles. Soluplus was also tested similarly without the allicin to determine the carrier effect. Dose-response curves of the treated cell lines in response to allicin, allicin-Soluplus micelles, and Soluplus prior to doxorubicin treatment for 48 and 72 h. As indicated by Table 2, allicin exerted an IC50 of 0.39 ± 0.14 mM on the normal myocardium cell line H9C2, and doxorubicin exerted an IC50 of 0.20 ± 0.04 µM after 48 h. The treatment with allicin in its free form prior to the doxorubicin treatment resulted in a drastic increase in doxorubicin IC50 to 1.12 ± 0.22 µM, with a P value ≤ 0.0001 as indicated by Table 3. While treatment with the allicin-Soluplus micelles before doxorubicin treatment did not change its IC50 (P ≥ 0.9999) after 48 h, prolonged exposure resulted in enhancing their chemoprotective effect, as doxorubicin IC50 was increased from 0.10 ± 0.03 µM to 1.02 ± 0.15 µM after 72 h, with a P value ≤ 0.0001, suggesting a time-dependent behavior of the allicin-Soluplus micelles. The unloaded Soluplus carrier showed no significant effect on doxorubicin IC50 on H9C2, suggesting that this IC50 shift is mainly associated with allicin under the tested conditions rather than the carrier alone on myocardial cells with doxorubicin administration. These results are particularly important for myocardial cells, as doxorubicin has been extensively reported for its cardiotoxicity. In fact, doxorubicin treatment is known for its dose-limiting side effects related to cardiac complications, including arrhythmias and myocardial infarction. This toxicity stems from its intrinsic cellular pathways that involve the induction of severe oxidative stress through the formation of reactive oxygen species63,64. Allicin, on the other hand, has been previously reported for its cardioprotective activity that involves vasorelaxation and improving cardiac function. Furthermore, allicin has also been reported for its antioxidant properties, all of which align with the side effects that stem from doxorubicin treatment30–32. Given together, the combination of allicin treatment with doxorubicin provides a rationale for enhancing the outcomes of doxorubicin by reducing its off-target adverse effects. It has been previously reported that the dual treatment of allicin and doxorubicin provides cardioprotection in in vivo models65. However, the investigation of the incorporation of nano-delivery systems in such dual treatment remains limited. As such, this work provides preliminary insight into the use of nanocarriers in combination-treatment settings involving doxorubicin and allicin. Table 2IC50 values on a panel of normal and cancer cell lines. Treated groups were incubated for 24 h with each treatment, followed by a 48-hour incubation with doxorubicin. Data was recorded in replicates and is expressed as mean ± SD.Allicin IC50 (mM)Control GroupTreated GroupsDoxorubicin IC50 (µM)Doxorubicin IC50 (µM) + Allicin-Soluplus micellesDoxorubicin IC50 (µM) + AllicinDoxorubicin IC50 (µM) + SoluplusCell LineH9C20.39 ± 0.140.20 ± 0.040.2 ± 0.041.12 ± 0.220.24 ± 0.05CACO20.09 ± 0.050.16 ± 0.070.14 ± 0.020.43 ± 0.170.33 ± 0.10DU1450.01 ± 0.0050.66 ± 0.100.20 ± 0.080.19 ± 0.040.30 ± 0.04 IC50 values on a panel of normal and cancer cell lines. Treated groups were incubated for 24 h with each treatment, followed by a 48-hour incubation with doxorubicin. Data was recorded in replicates and is expressed as mean ± SD. Table 3One-way ANOVA of IC50 values doxorubicin vs. the three treatment groups on a panel of normal and cancer cell lines. Data was recorded in replicates and is expressed as mean ± SD.One-way ANOVA of IC50 ValuesCell LinesDox vs. Dox + Allicin-Soluplus MicellesDox vs. Dox + AllicinDox vs. Dox + SoluplusP / SignificanceH9C2≥ 0.9999 / ns≤ 0.0001 / ****0.8813 / nsCACO20.9265 / ns0.0010 / **0.0127 / *DU145≤ 0.0001 / ****≤ 0.0001 / ****≤ 0.0001 / **** One-way ANOVA of IC50 values doxorubicin vs. the three treatment groups on a panel of normal and cancer cell lines. Data was recorded in replicates and is expressed as mean ± SD. In colorectal adenocarcinoma CACO2 cells, the treatment with the allicin-Soluplus micelles prior to doxorubicin did not exert a clear effect (P: 0.9265). This is mainly attributed to the minimal uptake of the micelles that was reported in Sect. 3.6 in CACO2, which may hinder the effect of allicin in its micellar form. However, treatment with allicin in its free form prior to doxorubicin treatment significantly increased its IC50 value (P: 0.0010), showing a protective metabolic pattern similar to that observed in H9C2 cells. A similar pattern was observed upon treatment with the unloaded micelles, with a less statistically significant effect as indicated in Table 3. Paradoxically, a chemosensitizing effect of allicin was observed in the prostate cancer model DU145, in which doxorubicin IC50 was strongly decreased upon treatment with both of the allicin-Soluplus micelles and allicin in its free form, with P values ≤ 0.0001 for both treatments upon comparing doxorubicin IC50 alone to its combination with each treatment. This result is compatible with the uptake result in 3.6, in which the highest uptake of the allicin-Soluplus micelles was observed in DU145 cells. The effect of allicin on doxorubicin response appeared to be cell-model dependent, with either a chemoprotective/attenuating or chemosensitizing pattern observed across the tested models. This variability may be influenced by cellular context, tumor heterogeneity, and differences in intracellular signaling pathways65–67. However, these mechanisms were not directly investigated in the present study and should therefore be interpreted as possible explanations only. Similarly, the extent to which micellar delivery enhances the effect of allicin appears to depend on the cellular model. Table 4 compares the effects of allicin-Soluplus micelles and free allicin on doxorubicin IC50 values. Table 4 The effects of allicin-Soluplus micelles and free allicin on doxorubicin IC50 values.Doxorubicin IC50 Values in response to Allicin-Soluplus Micelles vs. AllicinCell LinesP / SignificanceH9C2≤ 0.0001 / ****CACO20.0020 / **DU1450.7898 / ns The effects of allicin-Soluplus micelles and free allicin on doxorubicin IC50 values. In both H9C2 and CACO2 cells, the chemoprotective effect of allicin was observed in favor of its free form. Alternatively, while both forms of allicin (free and loaded into the micelles) yielded a chemosensitizing effect of doxorubicin on DU145, no statistically significant difference was observed between the two studied forms. As mentioned in Sect. 3.6, uptake of the allicin-Soluplus micelles was the least in CACO2 cells, followed by H9C2, and the highest uptake was observed in DU145, which partly explains the difference in responses towards this dual treatment under the studied conditions. Apoptosis analysis by flow cytometry Doxorubicin has been known for its induction of apoptosis via several pathways68,69. However, information on the effects of allicin on apoptosis induction by doxorubicin is limited. As shown in Fig. 10, in myocardial H9C2 cells, the highest apoptosis induction was observed following treatment with allicin-Soluplus micelles combined with doxorubicin and with allicin-Soluplus micelles alone. Although the IC50 values of doxorubicin increased upon allicin incorporation, apoptosis induction was still observed. This indicates that MTT and Annexin V/PI should not be interpreted as identical biological readouts: MTT mainly reflects metabolic activity and IC50 shifts, whereas Annexin V/PI measures phosphatidylserine exposure and membrane integrity at a defined time point70,71. Total populations of early apoptosis, late apoptosis, and necrotic cells of H9C2, CACO2, and DU145. Therefore, the H9C2 results are interpreted as a potential partial metabolic protective effect accompanied by detectable apoptosis induction. This phenomenon may also be related to the observed uptake of micelles in H9C2 cells, suggesting possible off-target uptake in normal cells because the current formulation lacks active targeting ligands. In both adenocarcinoma models, CACO2 and DU145, early apoptosis was greatest upon allicin treatment (P: 0.0012). Late apoptosis was mainly observed following treatment with allicin-Soluplus micelles combined with doxorubicin. In DU145 cells, the combination of allicin with doxorubicin not only showed greater cellular uptake but also enhanced treatment efficacy by exerting a chemosensitizing effect and inducing apoptosis. These results provide a platform for future investigation of drug-delivery systems in combination-treatment settings. In conclusion, Soluplus-based polymeric micelles were successfully prepared as a nanocarrier platform for allicin and demonstrated nanoscale size, acceptable dispersity, high apparent allicin loading, and short-term physical stability. The formulation showed cell-model-dependent modulation of doxorubicin response, with a chemosensitizing pattern in DU145 cells and a potential partial protective/metabolic response in H9C2 and CACO2 cells under the tested conditions. The observed uptake of micelles in H9C2 also suggests possible off-target uptake in normal cells because the current formulation lacks active targeting ligands These findings should be interpreted as preliminary in vitro evidence and require further mechanistic, analytical, stability, intracellular release, and in vivo validation. Author contributions Conceptualization, K.A.; methodology, B.A, D.A, T.S; validation, W.A; formal analysis, N.A; investigation, B.A; resources, K.A, W.A; data curation, K.A; writing—original draft preparation, K.A, B.Z.A; writing—review and editing, N.A; visualization, B.Z.A; supervision, K.A, W.A; project administration, K.A; All authors have read and agreed to the published version of the manuscript. Funding This research received no external funding. Data availability The raw data supporting the conclusions of this article will be made available by the authors on request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The raw data supporting the conclusions of this article will be made available by the authors on request.